I. Pappworth

发表

The Switch from Latent to Productive Infection in Epstein-Barr Virus-Infected B Cells Is Associated with Sensitization to NK Cell Killing

E. Wang, M. Rowe, I. Pappworth, 2006, Journal of Virology.

C3 Glomerulopathy and Related Disorders in Children Etiology-Phenotype Correlation and Outcomes

D. Gale, R. Malcomson, D. Kavanagh, 2021 .

Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy

N. Curtin, I. Kotsopoulos, A. Mukhopadhyay, 2022, Cancers.

Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice

E. Wang, V. Holers, B. Sivasankar, 2009, Molecular immunology.

Impaired Transporter Associated with Antigen Processing-Dependent Peptide Transport during Productive EBV Infection1

M. Ressing, M. Rowe, D. Koppers-Lalic, 2005, The Journal of Immunology.

Successful Renal Transplantation in Factor H Autoantibody Associated HUS with CFHR1 and 3 Deficiency and CFH Variant G2850T

N. Sebire, Austin Waters, D. Bockenhauer, 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Homodimeric Minimal Factor H: In Vivo Tracking and Extended Dosing Studies in Factor H Deficient Mice

D. Kavanagh, T. Malik, M. Pickering, 2021, Frontiers in Immunology.

A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice

V. Holers, Andreas M. Rossbach, L. Kulik, 2018, Immunobiology.

Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice

P. Barlow, J. Atkinson, D. Kavanagh, 2019, The Journal of clinical investigation.

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.

P. Barlow, D. Kavanagh, T. Goodship, 2010, Blood.

Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.

D. Ricklin, J. Lambris, T. Simmet, 2016, Immunobiology.

Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS).

J. Atkinson, D. Kavanagh, S. Lea, 2015, Molecular immunology.

Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21)

L. Kulik, I. Pappworth, C. Haluszczak, 2009, Molecular immunology.

C3 Glomerulopathy and Related Disorders in Children

R. Malcomson, D. Kavanagh, S. Johnson, 2021, Clinical journal of the American Society of Nephrology : CJASN.

Factor H autoantibodies in membranoproliferative glomerulonephritis.

P. Barlow, D. Kavanagh, M. Denton, 2012, Molecular immunology.

Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression.

V. Holers, B. Morgan, I. Pappworth, 2012, Immunobiology.

Murine Factor H Co-Produced in Yeast With Protein Disulfide Isomerase Ameliorated C3 Dysregulation in Factor H-Deficient Mice

P. Barlow, T. Malik, M. Pickering, 2021, Frontiers in Immunology.

An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy

N. Sheerin, M. Pickering, E. Wong, 2015, Kidney international.

Complement factor h autoantibodies and age-related macular degeneration.

I. Deary, A. Laude, A. Wright, 2010, Investigative ophthalmology & visual science.

Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?

N. Plant, P. Roversi, D. Kavanagh, 2012, Clinical journal of the American Society of Nephrology : CJASN.

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.

P. Barlow, D. Kavanagh, T. Goodship, 2010, Blood.

Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.

John D Lambris, T. Simmet, M. Anliker, 2016, Immunobiology.